Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma

Am J Hematol. 2011 Jul;86(7):627-30. doi: 10.1002/ajh.22039. Epub 2011 Jun 14.

Authors

Francine Foss¹, Madeleine Duvic, Elise A Olsen

Affiliation

¹ Department of Medical Oncology and Bone Marrow Transplantation, Yale Cancer Center, New Haven, Connecticut 06520, USA. francine.foss@yale.edu

PMID: 21674574
DOI: 10.1002/ajh.22039

No abstract available

Publication types

Meta-Analysis

MeSH terms

Antineoplastic Agents / administration & dosage*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Diphtheria Toxin / administration & dosage*
Interleukin-2 / administration & dosage*
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / mortality
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins / administration & dosage
Recurrence
Skin Neoplasms / drug therapy*
Skin Neoplasms / mortality
Time Factors

Substances

Antineoplastic Agents
Diphtheria Toxin
Interleukin-2
Recombinant Fusion Proteins
denileukin diftitox